About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology
Free SOHO Membership:
www.sohoonline.org
SOHO 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Videos
SOHO 2022
Myeloma
Lymphoma
Leukemia
MDS and MPN
Benign Hematology
SOHO 2021
Myeloma
Cellular Therapy
Solid Tumors
Leukemia
MDS
Benign Hematology
MPN
Lymphoma
SOHO 2020
Basic Science
Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
SOHO Highlights: State of the Art and Next Questions
SOHO 2019
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
SOHO 2018
Session I: Chronic Myeloid Leukemia
Session II: Myelodysplastic Syndromes
Session III: Myeloproliferative Neoplasms
Session IV: Acute Lymphoblastic Leukemia
Session V: Acute Myeloid Leukemia
Session VI: Multiple Myeloma
Session VIII: Non-Hodgkin Lymphoma
Session IX: Chronic Lymphocytic Leukemia
Session X: Research Topics
Plenary Sessions
Breakfast with the Expert
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
B
CLL Next Generation Reversible BTK Inhibitor, For Overcoming Acquired Resistance to Irreversible BTK Inhibitors
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Barbara Brandhuber
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Barbara Brandhuber
278 views
November 5, 2018
Oral Abstract CLL 200: LOXO-305
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Featured Video
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
Session IX: Chronic Lymphocytic Leukemia
13:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL State of the Art Update: Biology, Therapeutic Landscape, Infecti…
Feat.
F. Cymbalista
16:37
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Evolving Firstline Treatment for Patients with CLL
Feat.
N. Jain
15:20
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: The Chemoimmunotherapy Era in CLL is Over
Feat.
P. Thompson
14:11
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: Chemoimmunotherapy in CLL is Over? No
Feat.
B. Eichhorst
15:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Optimal Sequencing of Molecules in the Treatment in Chronic Lymphocy…
Feat.
A. Mato
07:53
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Risk of Infection with Ibrutinib in Patients with CLL: A Systematic …
Feat.
S. Ball
10:13
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL Next Generation Reversible BTK Inhibitor, For Overcoming Acquire…
Feat.
B. Brandhuber
13:08
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL Next Questions: Biology, MRD, Risk Stratification, New Molecules…
Feat.
F. Cymbalista
